{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-26-000006","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.906276+00:00","generated_at":"2026-05-15T02:41:29.350106+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC Therapeutics reports positive PIVOT-HD extension data: 52% slowing of HD progression at 10 mg votoplam","bullets":["Stage 2 HD participants showed 52% (10 mg) and 28% (5 mg) slowing on cUHDRS vs natural history at 24 months.","Mean NfL levels remained below baseline at 24 months for both doses, contrasting with natural history increases.","Safety data at Month 24 consistent with prior favorable safety profile; no treatment-related NfL increases.","Novartis has initiated global Phase 3 INVEST-HD study of votoplam (10 mg vs placebo, n≈770, primary endpoint cUHDRS at 36 months)."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-26-000006","json":"https://secwatch.observer/filing/0001070081-26-000006.json","markdown":"https://secwatch.observer/filing/0001070081-26-000006.md","text":"https://secwatch.observer/filing/0001070081-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/0001070081-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/tmb-20260428x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:41:29.350106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}